Physician profile
Omar Noor
NPI 1124319397
$4,547,418.48
in general payments reported to CMS, 2019-2025
33 companies · $1.2M in 2025
The $1.2M reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $126K · 2021: $294K · 2022: $678K · 2023: $1.0M · 2024: $1.1M · 2025: $1.2M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2.8M · Consulting Fee: $310K · Travel and Lodging: $135K · Food and Beverage: $65K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $64K · Honoraria: $4,510 · Education: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,789,683.80 |
| Consulting Fee | $309,887.58 |
| Travel and Lodging | $135,217.48 |
| Food and Beverage | $65,111.52 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $64,085.00 |
| Honoraria | $4,510.08 |
| Education | $493.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $513,838.74 | 2019-2025 | |
| Incyte Corporation | $421,188.34 | 2021-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $398,309.44 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $386,781.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $380,839.36 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $368,050.28 | 2019-2025 | Otezla, Otezla, Krystexxa |
| Lilly USA, LLC | $343,270.42 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Galderma Laboratories, L.P. | $314,503.60 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Pfizer INC. | $280,044.54 | 2019-2025 | |
| Ucb, INC. | $241,394.80 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $239,257.50 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $168,405.90 | 2022-2024 | Vtama, Tapinarof |
| Arcutis Biotherapeutics, INC. | $157,519.85 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $151,619.80 | 2024-2025 | Adbry, Anzupgo, Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64,732.20 | 2020-2025 | Siliq, Jublia, Cabtreo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $49,723.47 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $14,050.43 | 2024-2025 | |
| Epi Health, LLC | $12,339.57 | 2019-2022 | |
| Celgene Corporation | $10,121.68 | 2019 | |
| Almirall LLC | $9,478.00 | 2019-2025 | Klisyri, Seysara |
| Janssen Biotech, INC. | $8,746.83 | 2024-2025 | Tremfya |
| Organon LLC | $6,475.70 | 2024 | Vtama |
| Kowa Pharmaceuticals America, INC. | $3,750.00 | 2025 | Zoryve |
| Journey Medical Corporation | $1,412.74 | 2020-2025 | |
| Medimetriks Pharmaceuticals, INC. | $838.03 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $231.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.07 | 2023-2024 | Cyltezo, Spevigo |
| Revance Therapeutics, INC. | $78.12 | 2025 | Daxxify |
| Allergan, INC. | $73.04 | 2019-2021 | |
| Lnhc, INC | $58.52 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $38.59 | 2019-2024 | |
| Sebela Pharmaceuticals INC. | $18.40 | 2021 | |
| Sandoz INC. | $16.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Noor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.